Adjuvante und neoadjuvante Therapie des Melanoms

Die Behandlung des malignen Melanoms mit (neo-)adjuvanter Therapie stellt einen vielversprechenden Ansatz zur Verminderung von Rezidiven und Metastasierung dar. Gleichzeitig ist aufgrund des Risikos potenzieller Nebenwirkungen vorab eine Nutzen-Risiko-Abwägung unter Berücksichtigung des stadienabhängigen Rezidivrisikos erforderlich. Der Artikel zeigt die aktuelle Studienlage zur adjuvanten und neoadjuvanten Therapie auf.

Schlüsselwörter

Melanom - adjuvant - neoadjuvant - Nutzen-Risiko-Abwägung - pathologische Remission

• Literatur

• 1 Gershenwald JE, Scolyer RA. Correction to: Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond. Ann Surg Oncol 2018; 25: 993-994
• 2 Eggermont AMM, Kicinski M, Blank CU. et al. Five-Year Analysis of Adjuvant Pembrolizumab or Placebo in Stage III Melanoma. NEJM Evid 2022; 1 (11) 1-12
• 3 Larkin J, Del Vecchio M, Mandalá M. et al. Adjuvant Nivolumab versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results from CheckMate 238. Clin Cancer Res 2023; 29: 3352-3361
• 4 Dummer R, Hauschild A, Santinami M. et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib in Stage III Melanoma. N Engl J Med 2020; 383: 1139-1148
• 5 Luke JJ, Ascierto PA, Khattak A. et al. Pembrolizumab versus placebo as adjuvant therapy in stage IIB or IIC melanoma: Final analysis of distant metastasis-free survival in the phase 3 KEYNOTE-716 study. J Clin Oncol 2023; 41 (Suppl. 16) Abstr LBA9505
• 6 Kirkwood JM, Del Vecchio M, Weber J. et al. Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial. Nat Med 2023; 29: 2835-2843
• 7 Kirkwood JM, Weber J, Hoeller C. et al. Society for Melanoma Research, Philadelphia. 2023
• 8 Lee R, Rothwell DG, Jackson R. et al. Detection phae II/III trial: Circulating tumour DNA-guided therapy for stage II B/C melanoma after surgical recection. J Clin Oncol 2022; 40 (Suppl. 16)
• 9 Khattak A, Weber JS, Meniawy T. et al. Distant metastasis-free survival results from the randomized, phase 2 mRNA-4157-P201/KEYNOTE-942 trial. J Clin Oncol 2023; 41 (Suppl. 16)
• 10 Long GV, Carlino MS, Au-Yeung G. et al. NeoTrio: Randomized trial of neoadjuvant (NAT) pembrolizumab (Pembro) alone, in sequence (SEQ) with, or concurrent (CON) with dabrafenib plus trametinib (D+T) in resectable BRAF-mutant stage III melanoma to determine optimal combination of therapy. J Clin Oncol 2022; 40: 16S
• 11 Zara D, Pastò B, Garutti M. et al. 800P Number needed to treat (NNT) and number needed to harm (NNH) to estimate clinical efficacy and safety of new adjuvant (Adj) therapies for resected stage (St) II-III melanoma. Annals of Oncology 2022;
• 12 Blank CU, Rozeman EA, Fanchi LF. et al. Neoadjuvant Versus Adjuvant Ipilimumab Plus Nivolumab in Macroscopic Stage III Melanoma. Nature Medicine 2018; 24 (11) 1655-1661
• 13 van Akkooi ACJ, Blank C, Eggermont AMM. Neo-Adjuvant Immunotherapy Emerges as Best Medical Practice, and Will Be the New Standard of Care for Macroscopic Stage III Melanoma. European Journal of Cancer 2023; 182: 38-42
• 14 Amaria RN, Prieto PA, Tetzlaff MT. et al. Neoadjuvant Plus Adjuvant Dabrafenib and Trametinib Versus Standard of Care in Patients With High-Risk, Surgically Resectable Melanoma: A Single-Centre, Open-Label, Randomised, Phase 2 Trial. The Lancet. Oncology 2018; 19 (02) 181-193
• 15 Amaria RN, Menzies AM, Burton EM. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 2019; 20: e378-e389
• 16 Menzies AM, Amaria RN, Rozeman EA. et al. Pathological response and survival with neoadjuvant therapy in melanoma: a pooled analysis from the International Neoadjuvant Melanoma Consortium (INMC). Nat Med 2021; 27: 301-309
• 17 Blank CU, Versluis JM, Reijers ILM. et al. 3-year relapse-free survival, overall survival and long-term toxicity of (neo)adjuvant ipilimumab + nivolumab in macroscopic stage III melanoma (OpACIN trial). Ann Oncol 2019; 30 (Suppl. 05) v535
• 18 Rozeman EA, Menzies AM, Krijgsman O. et al. 18-months relaps free survival (RSF) and biomarker analyses of OpACIN-neo: a study to identify the optimal dosing schedule of neoadjuvant Ipilimumab (Ipi) + Nivolumab (Nivo) in stage III melanoma. Ann Oncol 2019; 30 (Suppl. 05) v851-v934
• 19 Versluis JM, Menzies AM, Sikorska K. et al. Survival update of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma in the OpACIN and OpACIN-neo trials. Ann Oncol 2023; 34: 420-430
• 20 Reijers ILM, Menzies AM, van Akkooi ACJ. et al. Personalized Response-Directed Surgery and Adjuvant Therapy After Neoadjuvant Ipilimumab and Nivolumab in High-Risk Stage III Melanoma: The PRADO Trial. Nature Medicine 2022; 28 (06) 1178-1188
• 21 Amaria RN, Menzies AM, Burton EM. et al. Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium. Lancet Oncol 2019; 20: e378-e389
• 22 Kakish H, Xu K, Ahmed FA. et al. Preoperative Therapy in Melanoma: Evolving Perspectives in Clinical Trials. Critical Reviews in Oncology/Hematology 2023; 104193
• 23 Huang AC, Orlowski RJ, Xu X. et al. A single dose of neoadjuvant PD-1 blockade predicts clinical outcomes in resectable melanoma. Nat Med 2019; 25 (03) 454
• 24 Patel S, Othus M, Chen Y. et al. Neoadjuvant-Adjuvant or Adjuvant-Only Pembrolizumab in Advanced Melanoma. N Engl J Med 2023; 388: 813-823
• 25 SUN Pharma Philogen innovating targeting. Nidleg Phase III PIVOTAL trial meets the study’s primary objective demonstrating statistically significant and clinically meaningful improvement in Recurrence-Free Survival for patients with locally advanced fully resectable melanoma. Accessed January 30, 2024 at: https://www.philogen.com/philogen/wp-content/uploads/2023/10/Press_release_PIVOTAL.pdf
• 26 Hauschild A. et al. Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases. Journal of Clinical Oncology 2024; 42 (Suppl. 17)
• 27 Blank CU. et al. Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial. Journal of Clinical Oncology 2024; 42 (Suppl. 17)